Viral Arthritis

Viral arthritis refers to joint inflammation caused directly by viral infection or by immune-mediated mechanisms triggered by viral pathogens. It is a common cause of acute polyarthritis, frequently misdiagnosed as early rheumatoid arthritis or other inflammatory arthropathies. Most viral arthritis is self-limiting, though certain viruses cause persistent or destructive joint disease. Accurate diagnosis prevents unnecessary immunosuppression and guides appropriate antiviral therapy where available.

Australian Epidemiology

Australia has a unique viral arthritis burden including endemic alphaviruses (Ross River virus, Barmah Forest virus) transmitted by mosquitoes in tropical and subtropical regions. Outbreaks occur seasonally, particularly in Queensland, northern NSW, Western Australia, and the Northern Territory. Parvovirus B19 and hepatitis B/C-associated arthritis are common nationally. Rubella-associated arthritis is rare due to childhood vaccination. Post-COVID-19 arthralgia and arthritis are increasingly recognised. Chikungunya is an emerging import from international travellers.

Mechanisms of Viral Joint Inflammation

Viral arthritis occurs via three main mechanisms: direct viral invasion of synovium (e.g., rubella, parvovirus, alphaviruses), immune complex deposition triggering synovitis (e.g., hepatitis B, C), and T-cell mediated autoimmune response triggered by molecular mimicry (e.g., post-viral reactive arthropathy). The synovial fluid may contain viral particles in direct infection, or be sterile with elevated lymphocytes in immune-mediated forms.

Key Causative Viruses in Australia

• Ross River Virus (RRV): Most common arboviral cause of arthritis in Australia (~4,000–8,000 notified cases/year). Alphavirus transmitted by Aedes and Culex mosquitoes. Causes polyarthritis, myalgia, rash, and fatigue. Can persist for months to years.
• Barmah Forest Virus (BFV): Second most common Australian arboviral arthritis. Similar clinical syndrome to RRV. Transmitted by mosquitoes in coastal and inland wetlands.
• Parvovirus B19: Common in adults with polyarthritis, particularly symmetrical small joint involvement mimicking RA. Associated with aplastic crisis in haemolytic anaemia.
• Hepatitis B Virus (HBV): Prodromal arthritis in acute HBV infection (serum sickness-like). Immune complex-mediated. Resolves with hepatitis onset.
• Hepatitis C Virus (HCV): Chronic arthritis, often with cryoglobulinaemia. Small joint, non-erosive. Often misdiagnosed as RA (false-positive RF common).
• SARS-CoV-2 (COVID-19): Post-COVID arthralgia and inflammatory arthritis increasingly recognised. Mechanism unclear; immune dysregulation proposed.
• Chikungunya: Alphavirus imported from endemic regions (Africa, Asia, Indian Ocean). Severe, incapacitating polyarthritis; can persist for years. Notifiable disease in Australia.

General Features

Viral arthritis typically presents with acute-onset polyarthritis, often with systemic features including fever, rash, malaise, and lymphadenopathy. Onset follows a prodromal viral illness by days to weeks. Joint involvement is usually symmetrical, affecting small joints (MCPs, PIPs, wrists, ankles), though large joints may be involved. Morning stiffness is common. Distinguishing features from RA include acute onset, viral prodrome, rash, and self-limiting course.

Virus-Specific Presentations

• Essential
  Full Blood Count and Inflammatory Markers

  FBC may show lymphocytosis (viral), leukopenia (parvovirus, SLE), or anaemia. ESR and CRP elevated but non-specific. CRP usually <50 in viral arthritis; markedly elevated CRP suggests bacterial septic arthritis.
• Essential
  Viral Serology

  Ross River virus IgM/IgG (ELISA); Barmah Forest virus IgM/IgG. Parvovirus B19 IgM/IgG. HBsAg, anti-HBc, HBV DNA. HCV antibody and RNA. Rubella IgM if unvaccinated. Chikungunya IgM/IgG (if travel history). All available through state reference laboratories in Australia.
• Essential
  Autoimmune Screen

  ANA, anti-dsDNA, RF, anti-CCP. RF may be transiently positive in HCV, parvovirus. Anti-CCP strongly suggests RA over viral arthritis. ANA and anti-dsDNA exclude SLE as cause.
• Essential
  Liver Function Tests

  Elevated transaminases suggest hepatitis B or C as cause. Bilirubin elevated in icteric hepatitis B. LFTs essential before immunosuppressive therapy.
• Available
  Synovial Fluid Analysis

  Performed if monoarthritis or septic arthritis cannot be excluded. Viral arthritis: WBC 2,000–20,000/mm³, predominantly lymphocytes; culture negative. Gram stain and culture mandatory to exclude bacterial infection.
• Available
  Joint Imaging

  X-rays of affected joints at baseline (usually normal in viral arthritis — no erosions). MRI for soft tissue or joint damage assessment. Erosive disease suggests alternative diagnosis (RA, septic arthritis).
• Referral
  Arboviral PCR (Acute Phase)

  Ross River and Chikungunya RNA detectable by PCR in first week of illness. Contact state public health laboratory. Notifiable disease reporting required for arboviral infections in all Australian states.

Red Flags Requiring Urgent Review

• Monoarthritis with fever → exclude septic arthritis (joint aspiration mandatory)
• Elevated transaminases + arthritis → hepatitis B or C serology urgently
• Travel history to chikungunya-endemic region + severe polyarthritis → notifiable disease; public health notification
• Cytopaenias + arthritis → parvovirus (aplastic crisis risk), SLE, or EBV
• Anti-CCP positive → RA diagnosis; do not label as viral arthritis

General Principles

Most viral arthritis is self-limiting and requires supportive care only. The mainstay is analgesia, rest during acute phase, and gradual return to activity. Immunosuppressive therapy (corticosteroids, DMARDs) should generally be avoided unless an autoimmune cause coexists or there is life-threatening complication. Identifying and treating the underlying viral infection is the most important disease-modifying intervention.

Non-Pharmacological Management

• Rest and activity modification: Acute phase: reduce weight-bearing activities. Subacute: gradual return to activity. Physiotherapy for joint protection and strengthening.
• Mosquito prevention (RRV/BFV): DEET-based repellent, long clothing, mosquito screens. Public health notification for arboviral cases.
• Heat and cold therapy: Ice for acute inflammation; warmth for persistent stiffness.
• Patient education: Reassure self-limiting course. Explain that fatigue may persist. Avoid NSAID overuse. Realistic timeline of recovery (RRV may take 6–12 months).

Pharmacological Management

NSAIDs are first-line for pain and inflammation in viral arthritis. Use at full anti-inflammatory dose for 2–4 weeks initially. Ibuprofen 400–600 mg 8-hourly or naproxen 500 mg 12-hourly with food. Add gastroprotection (omeprazole 20 mg daily) for prolonged use or high-risk patients.

Paracetamol as adjunct or sole analgesic in patients with NSAID contraindications (renal impairment, active peptic ulcer, hepatitis with coagulopathy). 1 g 6-hourly maximum. Caution with hepatic disease — reduce dose or avoid if severe hepatitis B/C.

Hydroxychloroquine (200–400 mg daily) may be considered for persistent arthritis (>3 months) in RRV or Chikungunya where NSAIDs are insufficient. Off-label use but supported by case series. Baseline ophthalmology assessment required.

Short-course corticosteroids (prednisolone 20–30 mg tapered over 2–4 weeks) may be used for severe functional impairment. Avoid if active viral replication (hepatitis B/C without antiviral cover) — risk of viral flare.

Ross River / Barmah Forest Virus

No specific antiviral therapy available. Management is supportive: NSAIDs, rest, graduated exercise. Hydroxychloroquine for persistent arthritis. Prognosis generally good though fatigue and arthralgia may persist for 6–12 months. No vaccine available in Australia.

Hepatitis B-Associated Arthritis

Acute HBV arthritis (prodromal phase) resolves spontaneously with clearance of acute infection. NSAIDs for symptom control. Chronic HBV with arthritis: initiate antiviral therapy (entecavir or tenofovir) — this is first priority. Arthritis usually improves with viral suppression. Do not give corticosteroids without antiviral cover (risk of HBV reactivation and fulminant hepatitis).

Hepatitis C-Associated Arthritis

HCV-associated arthritis is an indication for DAA therapy (e.g., Glecaprevir/Pibrentasvir 8–12 weeks or Sofosbuvir/Velpatasvir 12 weeks). Arthritis typically improves significantly post-SVR12. Hydroxychloroquine useful adjunct for persistent arthritis after SVR. Avoid methotrexate — hepatotoxic in HCV. Rituximab for cryoglobulinaemia vasculitis component.